Department of Pharmacology, Toxicology and Therapeutics
PhD, University of Texas, 1992
Postdoctoral, University of Texas, 1993-1994
Postdoctoral, Rutgers University, 1994-1996
Overview of Research Interests:
• Enzymes involved in the multiple pathways of hepatic and extrahepatic estrogen metabolism, and factors that modulate the activity and levels of these metabolizing enzymes.
• Molecular mechanisms underlying the carcinogenic and anticancer actions of some endogenously-formed estrogen metabolites.
• Unique physiological actions (e.g., neuroprotection, neuro-endocrine modulation, immune modulation) exerted by bioactive endogenous estrogen metabolites, and the estrogen receptor-independent mechanism of their actions.
• Identification of novel cellular proteins that can modulate the biological functions of estrogen receptors and their ligands.
Fu XM, Wang P, Fukui M, Long C, Yin L, Choi HJ and Zhu BT  Pancreas-specific protein disulfide isomerase (PDIp) is a major intracellular estrogen-storage protein that modulates the tissue levels of estrogen in the pancreas. Biochemical Journal 447: 115-123.
Choi HJ and Zhu BT  Cyclin B1/Cdc2 up-regulation is required for the induction of mitotic prometaphase arrest in human breast cancer cells treated with 2-methoxyestradiol. Biochimica et Biophysica Acta (BBA) - Molecular Cell Research 1823: 1306-1315.
Fu XM, Wang P and Zhu BT  Characterization of the estradiol-binding site structure of human protein disulfide isomerase (PDI). PLoS ONE 6(11): e27185.
Fu XM, Wang P and Zhu BT  Characterization of the estradiol-binding site structure of human PDIp: Indispensable role of the hydrogen bond between PDIp-His278 and estradiol 3-hydroxyl group in the binding interaction. Biochemistry 50: 106-115
Wang P, Wen Y, Han GZ, Sidhu PK and Zhu BT  Characterization of the estrogenic activity of non-aromatic steroids: Are there male-specific estrogen receptor modulators? British Journal of Pharmacology 158: 1796-1807.
Zhu BT, Han GZ, Shim JY, Wen Y and Jiang XR  Quantitative structure-activity relationship (QSAR) of various endogenous estrogen metabolites for human estrogen receptor α and β subtypes: Insights into the structural determinants favoring a differential subtype binding. Endocrinology 147: 4132-4150.
Liu ZJ, Lee WJ and Zhu BT  Selective insensitivity of ZR-75-1 human breast cancer cells to 2-methoxyestradiol: Evidence for Type II 17β-hydroxysteroid dehydrogenase as the underlying cause. Cancer Research 65: 5802-5811.
Han GZ, Liu ZJ, Shimoi K and Zhu BT  Synergism between the anticancer actions of 2-methoxyestradiol and microtubule-disrupting agents in human breast cancer. Cancer Research 65: 387-393.
Lee AJ, Cai MX, Thomas PE, Conney AH and Zhu BT  Characterization of the oxidative metabolites of 17β-estradiol and estrone formed by fifteen selectively-expressed human cytochrome P450 isoforms. Endocrinology 144: 3382-3398.
Lee AJ, Conney AH and Zhu BT  Human cytochrome P450 3A7 has a distinct high catalytic activity for the 16α-hydroxylation of estrone, but not 17β-estradiol. Cancer Research 63: 6532-6536.
Bao-Ting Zhu, PhD